Human TRAILR4/TNFRSF10D Antibody

Catalog # Availability Size / Price Qty
MAB633
MAB633-SP
Human TRAILR4/TNFRSF10D Antibody in Neutralization
1 Image
Product Details
Citations (14)
FAQs
Supplemental Products
Reviews (1)

Human TRAILR4/TNFRSF10D Antibody Summary

Species Reactivity
Human
Specificity
Detects human TRAIL R4/TNFRSF10D in ELISAs and Western blots. In sandwich immunoassays, less than 5% cross-reactivity with recombinant human (rh) TRAIL R1, rhTRAIL R2, TRAIL R3, rhTRAIL, rhTNF‑ alpha, and rhTNF-beta is observed.
Source
Monoclonal Mouse IgG1 Clone # 104918
Purification
Protein A or G purified from ascites
Immunogen
Mouse myeloma cell line NS0-derived recombinant human TRAIL R4/TNFRSF10D
Ala56-His211
Accession # Q9UBN6
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Endotoxin Level
<0.10 EU per 1 μg of the antibody by the LAL method.
Label
Unconjugated

Applications

Recommended Concentration
Sample
Flow Cytometry
2.5 µg/106 cells
Human whole blood granulocytes
CyTOF-ready
Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.
 

Human TRAIL R4/TNFRSF10D Sandwich Immunoassay

Recommended Concentration
Reagent
ELISA Capture (Matched Antibody Pair)
2-8 µg/mL 

Use in combination with:

Detection Reagent: Human TRAILR4/TNFRSF10D Biotinylated Antibody (Catalog # BAF633)

Standard: Recombinant Human TRAILR4/TNFRSF10D Fc Chimera Protein, CF (Catalog # 633-TR)

Neutralization
Measured by its ability to neutralize TRAIL R4/TNFRSF10D-mediated inhibition of cytotoxicity in the L‑929 mouse fibroblast cell line. The Neutralization Dose (ND50) is typically 0.3-1.8 µg/mL in the presence of 90 ng/mL Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera, 20 ng/mL of Recombinant Human TRAIL/TNFSF10, and actinomycin D.

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Data Example

Neutralization TRAIL R4/TNFRSF10D Inhibition of TRAIL/TNFSF10-induced Cytotoxicity and Neutralization by Human TRAIL R4/TNFRSF10D Antibody. View Larger

TRAIL R4/TNFRSF10D Inhibition of TRAIL/TNFSF10-induced Cytotoxicity and Neutralization by Human TRAIL R4/TNFRSF10D Antibody. In the presence of the metabolic inhibitor actinomycin D, Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera (Catalog # 633-TR) inhibits Recombinant Human TRAIL/TNFSF10 (Catalog # 375-TEC) induced cytotoxicity in the L-929 mouse fibroblast cell line in a dose-dependent manner (orange line). Under these conditions, inhibition of Recombinant Human TRAIL/TNFSF10 (20 ng/mL) activity elicited by Recombinant Human TRAIL R4/TNFRSF10D Fc Chimera (90 ng/mL) is neutralized (green line) by increasing concentrations of Human TRAIL R4/TNFRSF10D Monoclonal Antibody (Catalog # MAB633). The ND50is typically 0.3-1.8 µg/mL.

Reconstitution Calculator

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Preparation and Storage

Reconstitution
Reconstitute at 0.5 mg/mL in sterile PBS.
Reconstitution Buffer Available
Reconstitution Buffer 1 (PBS)
Catalog #
Availability
Size / Price
Qty
RB01
Shipping
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: TRAILR4/TNFRSF10D

Human TRAIL R4, also called decoy receptor 2 (DcR2) and TRUNND (TRAIL receptor with a truncated death domain), is a type I, TNF R family transmembrane protein, which is a receptor for TRAIL (APO2 ligand). In the TNF superfamily nomenclature, TRAIL R4 is designated as TNFRSF10D. TRAIL R4 is unique among the TRAIL receptors in that its cytoplasmic domain contains a truncated consensus death domain motif. Binding of TRAIL R4 does not result in an apoptotic signal. Overexpression of TRAIL R4 can protect cells bearing TRAIL R1 and/or TRAIL R2 from TRAIL-mediated apoptosis. The human soluble TRAIL R4/Fc chimera neutralizes the ability of TRAIL to induce apoptosis.

References
  1. Griffith, T.S. et al. (1998) Curr. Opin. Immunol. 10:559.
  2. Pan, G. et al. (1998) FEBS lett 424:41.
  3. Marsters, S.A. et al. (1997) Cur. Biol. 7:1003.
  4. Degli-Esposti, M.A. et al. (1997) Immunity 7:813.
Long Name
TRAIL Receptor 4
Entrez Gene IDs
8793 (Human)
Alternate Names
CD264 antigen; CD264; DcR2; DCR2decoy with truncated death domain; Decoy receptor 2; TNF receptor-related receptor for TRAIL; TNF-related apoptosis-inducing ligand receptor 4; TNFRSF10D; TRAIL R4; TRAILR4; TRAIL-R4; TRAILR4TRAIL receptor 4; TRUNDDTRAIL receptor with a truncated death domain; tumor necrosis factor receptor superfamily member 10D; tumor necrosis factor receptor superfamily, member 10d, decoy with truncateddeath domain

Product Datasheets

Citations for Human TRAILR4/TNFRSF10D Antibody

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

14 Citations: Showing 1 - 10
Filter your results:

Filter by:

  1. Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing steps
    Authors: L Danish, D Imig, F Allgöwer, P Scheurich, N Pollak
    PLoS ONE, 2018;13(6):e0198203.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  2. TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells.
    Authors: Tang X, Lu J, Tu H, Huang K, Fu R, Cao G, Huang M, Cheng L, Dai L, Zhang L
    Anticancer Res, 2014;34(2):729-34.
    Species: Rat
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  3. Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes.
    Authors: Neumann S, Hasenauer J, Pollak N, Scheurich P
    J Biol Chem, 2014;289(23):16576-87.
  4. TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells.
    Cancer Gene Ther., 2012;19(9):652-8.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  5. Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL).
    Authors: Zauli G, Rimondi E, Celeghini C, Milani D, Secchiero P
    J. Cell. Physiol., 2010;222(2):357-64.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  6. Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients.
    Authors: Stary G, Klein I, Kohlhofer S, Koszik F, Scherzer T, Mullauer L, Quendler H, Kohrgruber N, Stingl G
    Blood, 2009;114(18):3854-63.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  7. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
    Authors: Weinmann L, Wischhusen J, Demma MJ, Naumann U, Roth P, Dasmahapatra B, Weller M
    Cell Death Differ., 2008;15(4):718-729.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  8. Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanisms.
    Authors: Shankar S, Chen Q, Ganapathy S, Singh KP, Srivastava RK
    Mol. Cancer Ther., 2008;7(8):2328-38.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  9. Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells.
    Authors: Secchiero P, Melloni E, Corallini F, Beltrami AP, Alviano F, Milani D, D'Aurizio F, di Iasio MG, Cesselli D, Bagnara GP, Zauli G
    Stem Cells, 2008;26(11):2955-63.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  10. Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells.
    Authors: Barbarotto E, Corallini F, Rimondi E, Fadda R, Mischiati C, Grill V, Vaccarezza M, Celeghini C
    J. Cell. Biochem., 2008;104(2):595-605.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  11. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
    Authors: Toscano F, Fajoui ZE, Gay F, Lalaoui N, Parmentier B, Chayvialle JA, Scoazec JY, Micheau O, Abello J, Saurin JC
    Oncogene, 2008;27(30):4161-71.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  12. Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis.
    Authors: Locklin RM, Federici E, Espina B, Hulley PA, Russell RG, Edwards CM
    Mol. Cancer Ther., 2007;6(12):3219-28.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  13. Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells.
    Authors: Braun FK, Fecker LF, Schwarz C, Walden P, Assaf C, Durkop H, Sterry W, Eberle J
    J. Invest. Dermatol., 2007;127(10):2425-37.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry
  14. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma.
    Authors: Singh TR, Shankar S, Srivastava RK
    Oncogene, 2005;24(29):4609-23.
    Species: Human
    Sample Types: Whole Cells
    Applications: Flow Cytometry

FAQs

No product specific FAQs exist for this product, however you may

View all Antibody FAQs

Isotype Controls

Reconstitution Buffers

Secondary Antibodies

Reviews for Human TRAILR4/TNFRSF10D Antibody

Average Rating: 4 (Based on 1 Review)

5 Star
0%
4 Star
100%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Human TRAILR4/TNFRSF10D Antibody?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Human TRAIL R4/TNFRSF10D Antibody
By Anonymous on 07/17/2018
Application: WB Sample Tested: SW480 human colorectal adenocarcinoma cell line Species: Human

SW480 cells were treated with 5-FU (1 mg/ml) for indicated time points. Total cell lysates were subjected to western blot. PVDF membrane were probed with 1mm/ml Human TRAIL R4 Antibody (MAB633). A specific band was detected for TRAIL R4 at approximately 45-55 kDa. This experiment was conducted under reducing conditions.